BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie H, Song J, Du R, Liu K, Wang J, Tang H, Bai F, Liang J, Lin T, Liu J. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis. 2007;39:167-172. [PMID: 17161983 DOI: 10.1016/j.dld.2006.10.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Khalil A, Elgedawy J, Faramawi MF, Elfert A, Salama I, Abbass A, Elsaid H, Elsebaai H. Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions. Tumori 2013;99:100-7. [DOI: 10.1177/030089161309900117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
2 Wang XM, Yang LY, Guo L, Fan C, Wu F. p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer. 2009;115:4554-4563. [PMID: 19551892 DOI: 10.1002/cncr.24494] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
3 Riazalhosseini B, Mohamed Z, Apalasamy YD, Eng HS, Mohamed R. Association between microRNA-196A2 and microRNA-146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B. Pharmacogenetics and Genomics 2016;26:74-9. [DOI: 10.1097/fpc.0000000000000187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954. [PMID: 30412113 DOI: 10.1097/MD.0000000000012954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Maeda N, Maenaka K. The Roles of Matricellular Proteins in Oncogenic Virus-Induced Cancers and Their Potential Utilities as Therapeutic Targets. Int J Mol Sci 2017;18:E2198. [PMID: 29065446 DOI: 10.3390/ijms18102198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, Wu GH, Luk JM. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012; 18(30): 3923-3930 [PMID: 22912540 DOI: 10.3748/wjg.v18.i30.3923] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
7 Hua Z, Chen J, Sun B, Zhao G, Zhang Y, Fong Y, Jia Z, Yao L. Specific expression of osteopontin and S100A6 in hepatocellular carcinoma. Surgery. 2011;149:783-791. [PMID: 21310450 DOI: 10.1016/j.surg.2010.12.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
8 Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg. 2012;255:319-325. [PMID: 22241292 DOI: 10.1097/SLA.0b013e31823e3a1c] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
9 Imran M, Manzoor S, Parvaiz F. Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol 2014;27:404-11. [PMID: 25198668 DOI: 10.1089/vim.2014.0044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
10 Yin J, Lv X, Hu S, Zhao X, Liu Q, Xie H. Overexpression of serum response factor is correlated with poor prognosis in patients with gastric cancer. Hum Pathol 2019;85:10-7. [PMID: 30500416 DOI: 10.1016/j.humpath.2018.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers (Basel) 2020;12:E3379. [PMID: 33203146 DOI: 10.3390/cancers12113379] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
13 Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, Ajioka Y, Hatakeyama K. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol. 2008;39:1777-1783. [PMID: 18701136 DOI: 10.1016/j.humpath.2008.05.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
14 Lo RC, Ng IO. Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res. 2011;23:245-253. [PMID: 23359751 DOI: 10.1007/s11670-011-0245-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
15 Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol Carcinog. 2009;48:56-65. [PMID: 18506760 DOI: 10.1002/mc.20455] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
16 Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008;103:4-13. [PMID: 17890765 DOI: 10.1093/toxsci/kfm246] [Cited by in Crossref: 119] [Cited by in F6Publishing: 109] [Article Influence: 8.5] [Reference Citation Analysis]
17 舒宏, 康晓楠, 刘银坤. 肝癌转移、复发预测的蛋白质分子标志物. 世界华人消化杂志 2010; 18(13): 1350-1355 [DOI: 10.11569/wcjd.v18.i13.1350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Wen Y, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. Int J Biol Sci 2016;12:1121-8. [PMID: 27570486 DOI: 10.7150/ijbs.16445] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
19 Zhang X, Ye LH, Zhang XD. A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase. Acta Pharmacol Sin 2010;31:593-600. [PMID: 20364155 DOI: 10.1038/aps.2010.36] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
20 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Abu El Makarem MA, Abdel-aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Annals of Hepatology 2011;10:296-305. [DOI: 10.1016/s1665-2681(19)31541-8] [Cited by in Crossref: 40] [Article Influence: 4.0] [Reference Citation Analysis]
22 Abdel-Hafiz SM, Hamdy HE, Khorshed FM, Aboushousha TS, Safwat G, Saber MA, Seleem M, Soliman AH. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis. Asian Pac J Cancer Prev 2018;19:1021-7. [PMID: 29693976 DOI: 10.22034/APJCP.2018.19.4.1021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 11.4] [Reference Citation Analysis]
24 Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008;48:1834-1842. [PMID: 18972404 DOI: 10.1002/hep.22531] [Cited by in Crossref: 113] [Cited by in F6Publishing: 112] [Article Influence: 9.4] [Reference Citation Analysis]
25 Phillips RJ, Helbig KJ, Hoek KHVD, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18(26): 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18.i26.3389] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
26 Pritchett J, Harvey E, Athwal V, Berry A, Rowe C, Oakley F, Moles A, Mann DA, Bobola N, Sharrocks AD. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology. 2012;56:1108-1116. [PMID: 22488688 DOI: 10.1002/hep.25758] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
27 袁运生, 谢旻旗, 钱正昊, 张夕原, 严德珺, 俞雁. 骨桥蛋白: 肝脏疾病中的一个重要分子. 世界华人消化杂志 2011; 19(8): 814-819 [DOI: 10.11569/wcjd.v19.i8.814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Arriazu E, Ruiz de Galarreta M, Cubero FJ, Varela-Rey M, Pérez de Obanos MP, Leung TM, Lopategi A, Benedicto A, Abraham-Enachescu I, Nieto N. Extracellular matrix and liver disease. Antioxid Redox Signal 2014;21:1078-97. [PMID: 24219114 DOI: 10.1089/ars.2013.5697] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
29 Chen RX, Xia YH, Cui JF, Xue TC, Ye SL. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol. 2010;25:1435-1442. [PMID: 20659235 DOI: 10.1111/j.1440-1746.2010.06277.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
30 孙静云, 徐吉敏, 严明, 叶放. 骨桥蛋白与肝癌转移复发关系的研究进展. 世界华人消化杂志 2013; 21(16): 1498-1504 [DOI: 10.11569/wcjd.v21.i16.1498] [Reference Citation Analysis]
31 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
32 Pritchett J, Athwal VS, Harvey E, Martin K, Llewellyn J, Ireland P, Nicolaides A, Humphries MJ, Bobola N, Hanley NA, Piper Hanley K. Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells. PLoS One 2014;9:e100091. [PMID: 24971829 DOI: 10.1371/journal.pone.0100091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
33 Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44:22-30. [PMID: 23701387 DOI: 10.1111/hepr.12166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
34 Zhao L, Wang Y, Qu N, Huang C, Chen L. Significance of Plasma Osteopontin Levels in Patients with Bladder Urothelial Carcinomas. Mol Diagn Ther 2012;16:311-6. [DOI: 10.1007/s40291-012-0005-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
35 Mormile R. Hepatitis B virus (HBV) infection and multiple sclerosis: One more reason to undergo vaccination? Immunology Letters 2015;165:60-1. [DOI: 10.1016/j.imlet.2015.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Al-Qahtani A, Al-Anazi M, Viswan NA, Khalaf N, Abdo AA, Sanai FM, Al-Ashgar H, Al-Ahdal M. Role of single nucleotide polymorphisms of KIF1B gene in HBV-associated viral hepatitis. PLoS One. 2012;7:e45128. [PMID: 23028799 DOI: 10.1371/journal.pone.0045128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
37 Wang SY, Chen CL, Hu YC, Chi Y, Huang YH, Su CW, Jeng WJ, Liang YJ, Wu JC. High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. Cancers (Basel) 2019;11:E1549. [PMID: 31614906 DOI: 10.3390/cancers11101549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
38 El-din Bessa SS, Elwan NM, Suliman GAM, El-shourbagy SH. Clinical Significance of Plasma Osteopontin Level in Egyptian Patients with Hepatitis C Virus-related Hepatocellular Carcinoma. Archives of Medical Research 2010;41:541-7. [DOI: 10.1016/j.arcmed.2010.10.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
39 Chen BL, Zhang GY, Yuan WJ, Wang SP, Shen YM, Yan L, Gu H, Li J. Osteopontin expression is associated with hepatopathologic changes in Schistosoma japonicum infected mice. World J Gastroenterol 2011; 17(46): 5075-5082 [PMID: 22171141 DOI: 10.3748/wjg.v17.i46.5075] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
40 Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014;15:103-107. [PMID: 25249230 DOI: 10.1016/j.ajg.2014.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
41 Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012;130:2685-92. [PMID: 21780114 DOI: 10.1002/ijc.26301] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
42 Li N, Long Y, Fan X, Liu H, Li C, Chen L, Wang Z. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res 2009;28:122. [PMID: 19715608 DOI: 10.1186/1756-9966-28-122] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
43 Zhou C, Zhou HJ, Zhang XF, Lou LL, Ye QH, Zheng Y, Wang J, Zhu HT, Dong QZ, Jia HL, Zhu WW, Guo L, Zhao Y, Gao DM, Qin LX. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol 2013;20:929-37. [PMID: 23203407 DOI: 10.1245/s10434-012-2749-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
44 Yang P, Markowitz GJ, Wang XF. The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev 2014;1:396-412. [PMID: 25741453 DOI: 10.1093/nsr/nwu038] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
45 Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90. [PMID: 21953299 DOI: 10.1002/hep.24703] [Cited by in Crossref: 185] [Cited by in F6Publishing: 185] [Article Influence: 18.5] [Reference Citation Analysis]
46 Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta. 2010;411:675-678. [PMID: 20138033 DOI: 10.1016/j.cca.2010.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
47 Kim SH, Chung YH, Yang SH, Kim JA, Jang MK, Kim SE, Lee D, Lee SH, Lee D, Kim KM. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol. 2009;15:320-330. [PMID: 19783881 DOI: 10.3350/kjhep.2009.15.3.320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]